LMR Partners’s Novo Nordisk NVO Stock Holding History

LMR Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-63,871	Closed	-$2.35M	–	1698
2026 Q1	$2.35M	Sell	63,871 -36,129	-36%	-$1.71M	0.01%	824
2025 Q4	$5.09M	Buy	100,000 +98,594	+7,012%	+$5.04M	0.01%	567
2025 Q3	$78K	Buy	+1,406	New	+$82.3K	﹤0.01%	1294
2025 Q2	–	Sell	-40,000	Closed	-$2.72M	–	1566
2025 Q1	$2.78M	Buy	40,000 +15,001	+60%	+$1.24M	0.03%	580
2024 Q4	$2.15M	Sell	24,999 -38,534	-61%	-$4.17M	0.02%	583
2024 Q3	$7.56M	Buy	63,533 +5,398	+9%	+$720K	0.06%	272
2024 Q2	$8.3M	Sell	58,135 -503	-0.9%	-$66.7K	0.07%	240
2024 Q1	$7.53M	Buy	58,638 +54,404	+1,285%	+$6.48M	0.08%	232
2023 Q4	$438K	Buy	+4,234	New	+$419K	0.01%	662
2023 Q3	–	Sell	-71,686	Closed	-$6.31M	–	1007
2023 Q2	$5.8M	Buy	+71,686	New	+$5.86M	0.06%	241
2022 Q4	–	Sell	-14,400	Closed	-$717K	–	1221
2022 Q3	$717K	Sell	14,400 -50,000	-78%	-$2.68M	0.01%	814
2022 Q2	$3.59M	Buy	+64,400	New	+$3.57M	0.06%	359

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

LMR Partners's NVO Position: Q2 2026 in Review

LMR Partners sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 63,871 shares — an estimated $2.35M sold.

LMR Partners first reported a position in NVO in Q2 2022 and held it in 12 quarters. The position peaked at $8.3M in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

LMR Partners reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 63,871 Novo Nordisk shares in Q2 2026, an estimated $2.35M.
LMR Partners first reported a position in Novo Nordisk in Q2 2022 and held it in 12 quarters.
LMR Partners's Novo Nordisk position peaked at $8.3M in Q2 2024.
1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.